Sign In
Buy ORGS
$0.590
+0.0950 (+19.19%)
At Close: Jun 03, 2026
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio
10:52am, Thursday, 26'th Mar 2026
Plano, Texas--(Newsfile Corp. - March 26, 2026) - Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio
Critical Contrast: UCB (OTCMKTS:UCBJF) versus Orgenesis (NASDAQ:ORGS)
02:08am, Friday, 13'th Feb 2026
Orgenesis (NASDAQ: ORGS - Get Free Report) and UCB (OTCMKTS:UCBJF - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strengt
Orgenesis (NASDAQ:ORGS) Stock Price Up 300% – Time to Buy?
04:20am, Friday, 06'th Feb 2026
Orgenesis Inc. (NASDAQ: ORGS - Get Free Report) shares rose 300% during mid-day trading on Thursday. The stock traded as high as $0.60 and last traded at $0.60. Approximately 100 shares traded hands d
Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS)
02:08am, Tuesday, 06'th Jan 2026
Volatility and Risk eFFECTOR Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.44, suggesting that its sto
Statera Biopharma (NASDAQ:STAB) vs. Orgenesis (NASDAQ:ORGS) Financial Contrast
01:43am, Thursday, 18'th Dec 2025
Volatility and Risk Orgenesis has a beta of 3.16, suggesting that its stock price is 216% more volatile than the S&P 500. Comparatively, Statera Biopharma has a beta of 0.18, suggesting that its stock
Orgenesis (NASDAQ:ORGS) Trading 493.3% Higher – Here’s Why
03:00am, Wednesday, 22'nd Oct 2025
Orgenesis Inc. (NASDAQ: ORGS - Get Free Report)'s share price traded up 493.3% during trading on Tuesday. The stock traded as high as $0.89 and last traded at $0.89. 235 shares traded hands during tra
Strategic Acquisition Designed to Expand Access to Cost-Effective, Scalable Regenerative Medicine Treatments GERMANTOWN, MD / ACCESS Newswire / March 6, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
08:00am, Tuesday, 28'th Jan 2025
Funding Aimed at Accelerating Rollout of Decentralized CGT Platform GERMANTOWN, MD / ACCESS Newswire / January 28, 2025 / Orgenesis Inc . (OTCQX:ORGS) ("Orgenesis" or the "Company"), a global biotech
Orgenesis' CD19 CAR-T therapy, ORG-101, had a complete response (CR) of 82% in adults and 93% in pediatric patients with the incidence of severe Cytokine Release Syndrome (CRS) of 2% in adult patien
The strategic alliance aims to drive new-age innovation in wellness & longevity, backed by an investment commitment of up to $10 million over 3 years into both Orgenesis and the newly formed joint ven
Orgenesis Provides Business Update for the First Quarter of 2024
07:00am, Tuesday, 21'st May 2024
Accelerates rollout of POCare platform following partnership agreement with Germfree and acquisition regaining full ownership and control over Octomera Accelerates rollout of POCare platform following
Orgenesis Provides Year End Business Update
05:07pm, Monday, 15'th Apr 2024
M ajor transformation underway commencing with recent acquisition reasserting full ownership and control over Octomera
ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global l
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
08:30am, Monday, 18'th Mar 2024
GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announc
GERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announc
